Based on the available search results, there is no direct information regarding a person named “Yiola Marcou” or her specific expert insights on breast cancer therapy as of June 2026.
However, the field of breast cancer therapy is currently experiencing significant advancements in personalized care, particularly with:
Circulating Tumor DNA (ctDNA): The use of “liquid biopsy” is evolving to detect minimal residual disease (MRD) and monitor treatment responses.
Genomic Testing: Trials like OPTIMA are showing that for patients with low genomic risk scores, chemotherapy can be safely avoided, with 94% of patients remaining recurrence-free at five years.
HER2+ Treatment Personalization: Discussions are ongoing about how to tailor therapies to maximize cures while reducing toxicity for HER2-positive early breast cancer.
It is possible that “Yiola Marcou” is a clinician or researcher presenting on these topics in a specific webinar or educational series, such as the OncoAlert Horizons educational series or at a conference like the American Society of Breast Surgeons meeting.
If you can tell me where you heard this name or the specific conference or publication she was featured in, I can provide a more accurate and tailored answer.
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
Leave a Reply